Portfolio managment:Layout 1 14/1/10 20:10 Page 18
Business
References
at Wyeth. Charles has been with Wyeth for six University. Before joining Wyeth, Dr Brennan led
1 Dormer, C. Fostering years and has been part of the Discovery business a new multidisciplinary Discovery Strategic
Innovation – Transparency in
Team for five of these. In this role he heads up the Planning Group at FMC with responsibility for
Drug Discovery Can Boost
Discovery Operations, Portfolio Management and validation and prioritisation of target sites and
Productivity. Modern Drug
Discovery, vol. 7, no. 11 (2004).
Discovery Alliance Management functions. Prior oversight of high throughput assay development.
2 Ideker, T, Galitski, T and
to joining the Discovery group, Charles was Prior to that, Dr Brennan was Principal Scientist at
Hood, L. A new approach to Director, Research Planning, a role involved in American Cyanamid with 12 years’ experience
decoding life: systems biology.
implementing breakthrough initiatives in Wyeth applying a broad knowledge base in molecular
Annu Rev Genomics Hum
R&D. Prior to joining the Discovery group, biology and genomics to small molecule discovery.
Genet 2, 343-372 (2001).
3 Kitano, H. Systems biology: a
Charles was Director, Research Planning, a role
brief overview. Science 295,
involved in implementing breakthrough initiatives Roanna London is the Portfolio Manager for
1662-1664 (2002). in Wyeth R&D. Before joining Wyeth he had an Biological Technologies supporting both Biologic
4 Feuerstein, GF, Rutkowski, JL,
18-year career at SmithKline Beecham and Therapeutics and Systems Biology. In addition she
Walsh, FS, Stiles GL, Ruffolo,
GlaxoSmithKline and held a wide variety of busi- also manages Discovery’s Metabolic Diseases &
RR. The Role of Translational
Medicine and Biomarker
ness redesign roles and line positions within R&D. Hemophilia Research Portfolio. Roanna holds a
Research in Drug Discovery
His final role at GSK was as an Integration/ Master’s Degree in Biology from Harvard
and Development, American Redesign Partner in R&D, aligned to Project and University, a Certificate in Information Systems
Drug Discovery, 2(1), 23-28
Portfolio Management and R&D Strategy. Charles Management from Harvard University and a
(2007).
earned a Fellowship of the Institute of Medical Bachelor’s Degree in Biology from Colgate
5 Bouley, J. Wyeth and Scots
form translational medicine
Sciences while in the UK. He graduated from a University. Prior to coming to Wyeth, Roanna
collaborative, Drug Discovery
Post-Experience Course in Immunology at Chelsea worked at Rapid Micro Biosystems focusing on the
News May 2006. College, University of London. He has an MS and development of an automated imaging system for
6 Fox, S. High Throughput
an MPhil in Organizational Dynamics from the rapid detection of microbial contamination in the
Screening 2002: New
University of Pennsylvania. manufacture of pharmaceutical, biotechnology,
Strategies and Technologies.
Moraga, CA: Hightech Business
and personal care products.
Decisions (2002).
Dr Mark Beggs is Wyeth’s Programme Manager
7 Beggs M, Emerick VL and for the Translational Medicine Research
Archer JR. High Throughput
Collaboration based in Dundee UK. Mark holds
Screening in Industrialisation
a PhD in Clinical Biochemistry and a BA in
of Drug Discovery: from Target
Selection through Lead
Biochemistry both from Oxford University. He
Optimisation ed. Handen, JS.
was formerly Head of Consulting at The
Marcel Dekker Inc., New York Automation Partnership in Cambridgeshire UK.
p103-136 (2005).
Here he led a consulting team in delivering major
8 Archer, JR. Faculty or
change programmes for clients within
factory? Why industrialized
drug discovery is inevitable. J
Pharmaceutical Discovery and Biological pro-
Biomol Screen 4:235–237
duction with particular focus on the application
(1999). of manufacturing consultancy techniques in a
9 Peakman T, Franks S. White
Pharmaceutical Discovery environment. Two
C and Beggs M. Harnessing the
publicly citable projects on which he worked on
power of Discovery in large
pharmaceutical organisations.
at TAP were Wyeth’s new Screening Sciences
Closing the productivity gap.
project at Collegeville PA and GSK’s uHTS facil-
Drug Discovery Today (2003) ity at Tres Cantos near Madrid. Mark has an
8,5, 203-211 (2003).
additional 10 years’ direct experience in
Pharmaceutical Discovery, having worked for
Glaxo in North Carolina USA, Zeneca in
Alderley Park, UK and J&J in Beerse, Belgium.
His last Pharmaceutical position was as Director
of HTS for J&J in Belgium.
Dr Lynn Brennan is Wyeth’s Portfolio Manager for
Discovery Translational Medicine. Lynn earned a
PhD in Molecular Biology studying cellular onco-
genes at the Sloan Kettering Division of Cornell
University-Graduate School of Medicine and a BA
in Biology from Douglass College, Rutgers
18 Drug Discovery World Winter 2009/10
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88